StreetInsider.com News Articles

Form S-8 Acumen Pharmaceuticals,

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913317.html

Form S-8 Acumen Pharmaceuticals,

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913317.html

Form 10-Q Acumen Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912994.html

Form 10-Q Acumen Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912994.html

Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 9c

Wed, 12 Aug 2026 07:44:43 -0400

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 EPS of ($0.45), $0.09 worse than the analyst estimate of ($0.36).

For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.

Form 8-K Acumen Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26908760.html

Form 8-K Acumen Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26908760.html

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Wed, 12 Aug 2026 07:00:00 -0400

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027
Cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026, expected to support current clinical and operational activities into early 2027
Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Wed, 12 Aug 2026 07:00:00 -0400

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027
Cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026, expected to support current clinical and operational activities into early 2027
Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

Wed, 05 Aug 2026 16:00:00 -0400

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

Wed, 05 Aug 2026 16:00:00 -0400

To participate in the live conference call, please register using this link. After registration, you will be informed

Acumen Pharmaceuticals shares brain delivery antibody data at AAIC 2026

Wed, 15 Jul 2026 07:31:02 -0400

Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and clinical data at the Alzheimer's Association International Conference (AAIC) 2026 in London, including findings from its Enhanced Brain Delivery (EBD) program developed in collaboration with JCR Pharmaceuticals.

In studies using cynomolgus monkeys, three bispecific antibodies combining an anti-amyloid beta oligomer (AβO) antibody with anti-transferrin receptor fragments achieved greater brain exposure than the unmodified antibody alone. Lead candidate ACU401 showed 22-fold higher frontal cortex levels at three hours post-dose and 40-fold higher levels at 24 hours, with similar results observed in the hippocampus and putamen. No hematological findings associated with anemia were reported. Systemic

Acumen Pharmaceuticals shares brain delivery antibody data at AAIC 2026

Wed, 15 Jul 2026 07:31:02 -0400

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Wed, 15 Jul 2026 07:30:00 -0400

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy
EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions
No hematological safety signals observed in non-human primates, demonstrating low potential for anemia
ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer's disease

NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Wed, 15 Jul 2026 07:30:00 -0400

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacy
EBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions
No hematological safety signals observed in non-human primates, demonstrating low potential for anemia
ALTITUDE-AD patient experience data highlight unmet need in early Alzheimer's disease

NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 202

Tue, 07 Jul 2026 07:30:00 -0400

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present three key studies at the upcoming Alzheimer's Association International Conference (AAIC^®) 2026 in London. Shared in one oral and two poster presentations, the data highlight Acumen’s progress with JCR Pharmaceuticals (JCR), in developing next generation therapeutics through Enhanced Brain Delivery (EBD) technology and expanding the field’s understanding of early symptomatic AD through the patient lens. The conference will be

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 202

Tue, 07 Jul 2026 07:30:00 -0400

Form 4 Acumen Pharmaceuticals, For: Jun 15 Filed by: Porter Derrell

Wed, 17 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26660902.html

Form 4 Acumen Pharmaceuticals, For: Jun 15 Filed by: Porter Derrell

Wed, 17 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26660902.html

Form 144 Acumen Pharmaceuticals, Filed by: Porter Derrell

Wed, 17 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26659751.html

Form 144 Acumen Pharmaceuticals, Filed by: Porter Derrell

Wed, 17 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260617/26659751.html

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Wed, 17 Jun 2026 12:30:00 -0400

- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease

- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027

HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Wed, 17 Jun 2026 12:30:00 -0400

- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease

- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Wed, 17 Jun 2026 12:30:00 -0400

- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease

- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Wed, 17 Jun 2026 12:30:00 -0400

- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease

- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027